

**RESMED ANNOUNCES PROMOTION OF KIERAN GALLAHUE  
TO PRESIDENT OF RESMED GLOBAL**

SYDNEY, Australia, September 9, 2004 - ResMed Inc. (NYSE: RMD) announced today that Kieran T. Gallahue has been promoted from President and Chief Operating Officer of the Americas to President of ResMed Global. As President of ResMed Global, Mr. Gallahue will assume responsibility for global operations, new business development, and product innovation. He will continue to report to Peter C. Farrell, PhD, and Dr. Farrell will continue to lead the global business as Chairman and Chief Executive Officer. Mr. Gallahue will temporarily relocate to ResMed's Sydney, Australia, offices as he transitions into his new role.

Since January 2003, Mr. Gallahue has been responsible for managing ResMed's business operations in the US, Canada, and Latin America, including sales, marketing, clinical education, new business development, operations, and finance. "Kieran has been a real asset in managing business in the Americas," stated Dr. Farrell. "I am confident that Kieran will succeed in bringing his disciplined and focused approach to bear on our global operations."

"Peter is a visionary entrepreneur and a passionate leader who has been instrumental in the success of ResMed," stated Mr. Gallahue. "We have a strong management team throughout the world, and I look forward to working with that team to strengthen our enviable position in the global sleep market."

Mr. Gallahue joined ResMed in January 2003 from San Diego-based Nanogen, Inc, where he held a number of positions, including President, Chief Financial Officer, and Vice President Strategic Marketing. Before joining Nanogen, he led the critical care business division for Instrumentation Laboratory. In addition, Mr. Gallahue held various sales and marketing management positions with both General Electric and Proctor & Gamble. Mr. Gallahue holds a Bachelor's Degree in Economics and Accounting from Rutgers University and an MBA from Harvard Business School.

ResMed is a leading manufacturer of medical equipment for the diagnosis, treatment, and management of sleep-disordered breathing. We are dedicated to improving awareness among patients and healthcare professionals of the potentially serious health consequences of untreated sleep-disordered breathing and to developing innovative technology to improve the lives of those who suffer from this condition. For more information on ResMed, please visit [www.resmed.com](http://www.resmed.com).

Statements contained in this release that are not historical facts are "forward-looking" statements as contemplated by the Private Securities Litigation Reform Act of 1995. Those risks and uncertainties are discussed in the Company's Annual Report on Form 10-K for its most recent fiscal year and in other reports the Company files with the U.S. Securities & Exchange Commission. Those reports are available on the Company's Web site.

Contact:  
Hillary Theakston  
Director of Investor Relations  
Tel. +1 (858) 746-2610  
Email [hillaryt@resmed.com](mailto:hillaryt@resmed.com)